Treatment
Penpulimab clinical trials
We’re tracking 17 recruiting studies that include Penpulimab, each written for real people, not researchers, below.
Recruiting studies
- NCT06825494RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new medication for people with advanced solid tumors that have stopped responding to standard treatments. It aims to see if the drug can shrink tumors or slow their growth.
Hefei, AnhuiAges 18 years+ - NCT05862337RecruitingPhase 3
New immune plus anti-cancer pills to prevent liver cancer returning
This Phase 3 trial studies anlotinib capsules plus penpulimab (an immune therapy) to help prevent hepatocellular carcinoma from coming back after it has been fully removed or fully destroyed. It may help high-risk patients lower the chance of recurrence and improve survival.
Bengbu, AnhuiAges 18–75 - NCT06821503RecruitingPhase 1/Phase 2
Study of LM-108 with chemo for advanced pancreatic cancer
This trial tests a new drug called LM-108 combined with chemotherapy for people with advanced pancreatic cancer that hasn't been treated before. The goal is to see if it's safe and may help shrink tumors or stop them from growing.
Beijing, Beijing MunicipalityAges 18 years+ - NCT05949931RecruitingPhase 2
Pianzumab plus AVD for newly diagnosed advanced Hodgkin lymphoma
This trial tests whether adding pianzumab to standard AVD chemotherapy works better for newly diagnosed advanced classic Hodgkin lymphoma. It may help people control the cancer and prevent it from coming back, and it will compare outcomes while tracking side effects.
Guangzhou, GuangdongAges 18 years+ - NCT06051851RecruitingPhase 2
Study of penpulimab, anlotinib, and chemo for advanced pancreatic cancer
This trial tests a combination of immunotherapy (penpulimab), a targeted therapy (anlotinib), and two chemotherapy drugs (nab-paclitaxel and gemcitabine) as a first treatment for pancreatic cancer that has spread. It aims to see if this new combination works better than standard care.
Nanjing, JiangsuAges 18 years+ - NCT05229003RecruitingPhase 2
Irinotecan, anlotinib, and pembrolizumab-like drug for advanced colon cancer
This Phase 2 study tests adding anlotinib and penpulimab to irinotecan for colorectal cancer that has come back or spread after earlier chemotherapy. It may help shrink tumors and control the disease when standard first-line treatment no longer works.
Shanghai, Shanghai MunicipalityAges 18–85 - NCT05260671RecruitingPhase 2
Penpulimab plus cetuximab for advanced head and neck cancer
This trial studies penpulimab (an immune medicine) combined with cetuximab (an antibody drug) for recurrent or metastatic squamous cell head and neck cancer that cannot be treated with surgery or radiation. It aims to shrink tumors and improve survival in people whose tumor shows a specific immune marker (PD-L1).
Changchun, JilinAges 18–80 - NCT05494060RecruitingPhase 2
Adjuvant chemo plus immunotherapy for ctDNA-positive stomach cancer
This trial tests whether adding an anti-cancer immune treatment and another targeted drug to standard chemotherapy after surgery can lower the chance of cancer coming back. It is for people whose blood test (ctDNA) shows leftover cancer-related DNA after surgery.
Nanjing, JiangsuAges 18–75 - NCT05576480RecruitingPhase 2
Immunotherapy plus chemotherapy before surgery for rectal cancer without mismatch repair
This Phase 2 study tests penpulimab (an immunotherapy medicine) given with CAPEOX chemotherapy before surgery for rectal cancer that is “MSS” (not the mismatch-repair type). It aims to shrink the tumor and improve outcomes by treating before the operation.
Shanghai, None SelectedAges 18–75 - NCT06081673RecruitingPhase 2
Penpulimab plus chemo before and after surgery for head and neck cancer
This trial tests a combination of penpulimab (an immunotherapy drug) and chemotherapy before and after surgery for head and neck cancer. The goal is to see if this approach can improve treatment outcomes for people with resectable (removable by surgery) cancers.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06586242RecruitingPhase 2
Penpulimab, anlotinib, and chemo before surgery for esophageal cancer
This trial tests a combination of three drugs (penpulimab, anlotinib, and chemotherapy) given before surgery to shrink esophageal cancer. It is for people with locally advanced cancer who have not had treatment before.
Xi'an, Shaan'xiAges 18–75 - NCT06767800RecruitingPhase 2
Study of TQB2102 with immunotherapy for HER2-positive gastroesophageal cancer
This trial tests a new combination of drugs (TQB2102, benmelstobart, and pembrolizumab) with or without chemotherapy for people with HER2-positive gastroesophageal cancer that cannot be removed by surgery or has spread. It aims to see if this combination is more effective than current treatments.
Fuyang, AnhuiAges 18–75 - NCT05214222RecruitingPhase 2
New treatment for advanced esophageal cancer after past therapy
This Phase 2 trial tests penpulimab plus chemotherapy (with or without an added targeted pill called anlotinib) in people with advanced esophageal squamous cell carcinoma. It aims to slow tumor growth and improve outcomes, especially for patients who can’t have curative surgery or radiation.
Guangzhou, GuangdongAges 18–75 - NCT05167994RecruitingPhase 2
Pre-surgery radiation plus an anti-cancer drug for soft tissue sarcoma
This Phase 2 trial tests whether giving radiation before surgery, along with anlotinib and penpulimab, can improve treatment for localized soft tissue sarcoma. It may help shrink or control the tumor before conservative surgery.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06114225RecruitingPhase 2
Immunotherapy and radiation before lung surgery for osteosarcoma
This trial tests a combination of immunotherapy and targeted radiation before surgery for osteosarcoma that has spread to the lungs. It aims to see if this approach can help shrink or control the lung tumors and make surgery more effective.
Shanghai, Shanghai MunicipalityAges 10–65 - NCT06444009RecruitingPhase 2
Immunotherapy and chemo before surgery for head and neck cancer
This trial tests whether giving immunotherapy along with chemotherapy before surgery can help treat locally advanced head and neck cancer that can be removed. The goal is to see if this combination shrinks tumors and improves outcomes.
Chengdu, SichuanAges 18–75 - NCT06943820RecruitingPhase 1/Phase 2
AK129 combination therapy for advanced solid tumors
This trial tests a new combination of drugs (including AK129) for people with advanced solid tumors, specifically lung cancer, head and neck cancer, or colorectal cancer. It is for those who have already tried a platinum chemo and a PD-1/PD-L1 drug but their cancer got worse.
Shenyang, LiaoningAges 18–75
What Penpulimab is being studied for
Conditions with recruiting Penpulimab studies.
Common questions
- Are there clinical trials studying Penpulimab?
- Yes. Clin2 currently lists 17 recruiting studies that include Penpulimab, drawn from the U.S. registry and rewritten for real people so you can see what each is testing and who it's for.
- How do I know if I qualify for a Penpulimab trial?
- Each study lists its own eligibility criteria — rules about condition, age, and prior treatments. On every Clin2 trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Is Penpulimab an approved treatment?
- A drug being studied in a trial may be investigational (still being tested) or already approved and being studied for a new use. Each study page explains what phase it's in. Clin2 does not provide medical advice — talk with your doctor about whether Penpulimab or a specific trial is right for you.
Related treatments
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. A drug appearing here is being studied in a trial and may be investigational. Talk with your doctor about whether a specific treatment or trial is right for you.